Skip to main content

Table 1 Clinical and biological characteristics of the study group. Patients were grouped according to the absence/presence of lung parenchymal changes on chest X-ray (stage I vs. stage II-III) and clinical phenotype (acute vs. insidious onset)

From: Immunoexpression of TGF-β/Smad and VEGF-A proteins in serum and BAL fluid of sarcoidosis patients

 

Stage I

Stages II-III

Acute onset

Insidious onset

n = 30

n = 27

n = 29

n = 28

Gender

15 F 15 M

11 F 16 M

15 F 14 M

11 F 17 M

Age

38.63 ± 8.84

42.88 ± 11.64

37.29 ± 12.06

36.62 ± 7.12

FEV1 [% pred.]

94.75 ± 14.01

92.30 ± 15.33

96.81 ± 14.76

90.33 ± 13.93

FVC [% pred.]

106.10 ± 12.51

102.19 ± 15.32

108.62 ± 12.44

99.81 ± 14.23

FEV1/FVC

0.75 ± 0.07

0.74 ± 0.07

0.74 ± 0.07

0.74 ± 0.06

DLCOc [% pred.]

-

93.25 ± 16.33

-

94.15 ± 17.58

BAL-L%

32.6 ± 16.74

28. 88 ± 17.10

36.48 ± 16.38

24.99 ± 15.90

BALF CD4+/CD8+

7.60 ± 4.55

4.78 ± 4.12

8.39 ± 4.56

4.42 ± 3.68

Ca2+S [mmol/l]

2.43 ± 0.08

2.38 ± 0.23

2.39 ± 0.17

2.43 ± 0.15

Ca2+U [mmol/24 h]

5.15 ± 2.33

4.64 ± 2.96

4.27 ± 2.60

5.51 ± 2.67

  1. Abbreviations: BALF, bronchoalveolar lavage fluid, BAL-L% % of BAL lymphocytes, CD cluster of differentiation, DLCOc lung diffusion capacity for carbon monoxide corrected for haemoglobin concentration, FEV 1 forced expiratory volume in first second of expiration, FVC forced vital capacity, pred predicted, S serum, U urine